Literature DB >> 27779083

Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.

Maren Paulmann, Maja Mockenhaupt1.   

Abstract

Severe cutaneous adverse reactions (SCAR) are known for a high morbidity and mortality. They may be life-threatening for the affected patient and difficult to accomplish for the patient's family and the treating physician. Such conditions include not only bullous reactions like toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), but also acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS). Since clinical pattern, etiology, prognosis and treatment differ among these severe skin reactions, a clear diagnosis based on a comprehensive clinical examination, skin biopsy, and specific laboratory tests is necessary. Because most of these reactions are caused by drug intake, a thorough history of medication use has to be obtained. However, there are cases with an infectious or idiopathic cause. In any case it is crucial to identify the most likely cause and rapidly discontinue the inducing agent, if a drug cause is suspected. This is associated with the patient`s prognosis which is often poor for bullous reaction. In addition, patient's age, underlying conditions, and the extent of skin detachment play a major role in terms of prognosis. Severe cutaneous adverse reactions are T-cell-mediated reactions, and certain alleles of human leukocyte antigens (HLA) are involved in the activation of T-cells with cytotoxic effect. The therapeutic options depend on the clinical diagnosis. For all reactions a symptomatic and adequate supportive therapy is necessary, in some cases a systemic immunomodulating therapy can be useful. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Severe cutaneous adverse reactions (SCAR); Stevens-Johnson syndrome (SJS); acute generalizedzzm321990exanthematous pustulosis (AGEP); drug reaction with eosinophilia and systemic symptoms (DRESS).; toxic epidermal necrolysis (TEN)

Mesh:

Year:  2016        PMID: 27779083     DOI: 10.2174/1381612822666160928125152

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

Review 1.  [Severe skin reactions due to new medications].

Authors:  M Mockenhaupt; M Paulmann
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

2.  Treatment of severe drug reactions by hemodialysis.

Authors:  Rokea A El-Azhary; Michael Z Wang; Ashley B Wentworth; LaTonya J Hickson
Journal:  Int J Dermatol       Date:  2017-11-22       Impact factor: 2.736

3.  A case of bortezomib (Velcade)-induced Stevens-Johnson syndrome confirmed by patch test.

Authors:  Gil-Soon Choi; Ho Sup Lee; Hee-Kyoo Kim
Journal:  Asia Pac Allergy       Date:  2021-04-21

4.  Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.

Authors:  Elizabeth J Phillips; Chonlaphat Sukasem; Michelle Whirl-Carrillo; Daniel J Müller; Henry M Dunnenberger; Wasun Chantratita; Barry Goldspiel; Yuan-Tsong Chen; Bruce C Carleton; Alfred L George; Taisei Mushiroda; Teri Klein; Roseann S Gammal; Munir Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2018-02-02       Impact factor: 6.875

Review 5.  Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.

Authors:  Teri A Manolio; Carolyn M Hutter; Mark Avigan; Ricardo Cibotti; Robert L Davis; Joshua C Denny; Lois La Grenade; Lisa M Wheatley; Mary N Carrington; Wasun Chantratita; Wen-Hung Chung; Andrea D Dalton; Shuen-Iu Hung; Ming Ta Michael Lee; J Steven Leeder; Juan J L Lertora; Surakameth Mahasirimongkol; Howard L McLeod; Maja Mockenhaupt; Michael Pacanowski; Elizabeth J Phillips; Simone Pinheiro; Munir Pirmohamed; Cynthia Sung; Wimon Suwankesawong; Lauren Trepanier; Santa J Tumminia; David Veenstra; Rika Yuliwulandari; Neil H Shear
Journal:  Clin Pharmacol Ther       Date:  2017-11-06       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.